Market news

Gossamer Bio (GOSS) said late Wednesday it has submitted a new drug application to the US Food and D

SAN DIEGO, September 23, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in September 2026 for seralutinib for the treatme

Detailed price information for Gossamer Bio Inc (GOSS-Q) from The Globe and Mail including charting and trades.

SAN DIEGO, September 16, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that Greg Ciongoli has been appointed to the Company's Board of Directors, effective September 16, 2026. Mr. Ciongoli will also serve as a member of the Audit Committee.

SAN DIEGO, September 04, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the Cantor Global Healthcare Conference to take place on September 9-11, 2026.

Gossamer Bio, Inc. (NASDAQ:GOSS) announced a structured private placement on August 21 that could generate up to approximately $250 million in gross proceeds. However, Gossamer Bio, Inc. (NASDAQ:GOSS) divided the financing into three stages, leaving most of the headline amount dependent on regulatory milestones. At the initial closing, Gossamer Bio, Inc. (NASDAQ:GOSS) expects approximately $25 […]

The proceeds will help advance seralutinib's clinical development and potential commercialisation.

Gossamer Bio has structured the financing around key seralutinib regulatory milestones, with $150 million committed and another $100 million potentially available if the pulmonary arterial hypertension drug receives FDA approval. Key Investor TakeawaysGossamer Bio (NASDAQ:GOSS) has secured up to $250 million through a structured private placement tied to seralutinib’s regulatory progress.

Gossamer Bio (GOSS) shares were up 10% in Friday's premarket trading after the company said it has a

SAN DIEGO, August 21, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it has entered into a securities purchase agreement with certain new and existing institutional investors for a private placement financing e

For Gossamer Bio, the average analyst Fair Value has shifted from about US$3.86 to about US$1.66 per share, which marks a meaningful reset in price targets. Research commentary links this move to a split view on risk, funding and execution, with more cautious analysts focusing on dilution and going concern warnings, while bullish voices still point to the seralutinib regulatory path and balance sheet work. As you read on, you will see how these changing assumptions shape the evolving Gossamer...

Detailed price information for Gossamer Bio Inc (GOSS-Q) from The Globe and Mail including charting and trades.

Gossamer Bio (GOSS) delivered earnings and revenue surprises of -100.00% and +171.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Gossamer Bio: Q2 Earnings Snapshot

SAN DIEGO, August 13, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the second quarter ended June 30, 2026, and provided a business update.

Gossamer Bio (GOSS) shares are in focus after the company detailed plans to submit an NDA for seralutinib in pulmonary arterial hypertension, reacquired global rights to the drug, and outlined recent shareholder approvals. See our latest analysis for Gossamer Bio. Gossamer Bio’s recent FDA meeting update and plan to submit an NDA for seralutinib have come after a tough period, with the stock’s 1 year total shareholder return down 91.53% and 5 year total shareholder return down 97.95%...

Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $97.4 million. Prelude Therapeutics (NASDAQ:PRLD) shares moved

(Updates with the stock move in the headline and the first two paragraphs.) Gossamer Bio's (GOSS)

Gossamer Bio (GOSS) has an average rating of overweight and mean price target of $3.86, according to

Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market session. The company's market cap stands at $66.4 million. ProMIS Neurosciences (NASDAQ:PMN) shares increased by

Gossamer Bio plans a September 2026 NDA filing for seralutinib following FDA feedback and reacquires global rights.

Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular session. The company's market cap stands at $100.9 million. Gossamer Bio (NASDAQ:GOSS) shares moved upwards by

Gossamer Bio Inc. (NASDAQ:GOSS) shares surged 25% on Monday after the biotechnology company provided a positive regulatory update on its lead drug candidate, seralutinib, and announced it had regained full global rights to the therapy.